Amycretin vs CagriSema: Research Compared

The short answer

Amycretin and CagriSema are both investigational candidates from Novo Nordisk, and both engage two of the same biological pathways: the GLP-1 receptor and the amylin receptor. The core difference is structural. Amycretin is described as a unimolecular, or single-molecule, agent that targets both receptors on its own. CagriSema is a co-formulation that combines two separate molecules, cagrilintide, an amylin analogue, with semaglutide, a GLP-1 receptor agonist, in one preparation.

So the comparison is really single molecule versus two-drug combination, with both approaches aimed at the same receptor pair. Neither is approved in Australia. Both are referenced here strictly as laboratory research compounds for in-vitro and non-human study, not for human use.

What is amycretin?

Amycretin is a Novo Nordisk candidate that the company describes as a long-acting, unimolecular GLP-1 and amylin receptor agonist. Unimolecular means a single engineered molecule is designed to activate both receptors, rather than relying on two separate drugs combined together.

Amycretin has been studied in more than one format, including subcutaneous and oral forms. Novo Nordisk announced plans to advance both the subcutaneous and oral candidates into later-stage clinical development for weight management. As a research reference, amycretin is of interest largely because of this single-molecule design, which differs from the combination approach used by CagriSema.

Amycretin at a glance

• Developer: Novo Nordisk
• Design: single-molecule (unimolecular) agent
• Targets: GLP-1 receptor and amylin receptor
• Formats studied: subcutaneous and oral
• Australian status: not approved, not on the ARTG

What is CagriSema?

CagriSema is a Novo Nordisk co-formulation that brings together two distinct molecules in a single preparation: cagrilintide, a long-acting amylin analogue, and semaglutide, a GLP-1 receptor agonist. Rather than one molecule acting on two receptors, CagriSema pairs an amylin-pathway agent with a GLP-1-pathway agent.

CagriSema has been studied through Novo Nordisk's REDEFINE clinical program, which includes several separate trials with different populations and designs. One of these, an open-label head-to-head study, did not meet its primary endpoint, which illustrates that late-stage candidates can produce mixed trial results. For research reference, the defining feature of CagriSema is that it is a combination of two established peptide classes.

CagriSema at a glance

• Developer: Novo Nordisk
• Design: co-formulation of two molecules
• Components: cagrilintide (amylin analogue) plus semaglutide (GLP-1 agonist)
• Clinical program: REDEFINE series of trials
• Australian status: the co-formulation is not approved, not on the ARTG

Single molecule versus co-formulation

This is the central contrast between the two. Amycretin is built as one molecule that carries activity at both the GLP-1 and amylin receptors. CagriSema reaches the same two pathways by combining two different molecules, each contributing its own receptor activity, within one formulation.

From a research-design perspective, the two approaches raise different questions. A single-molecule agonist concentrates both activities into one defined structure, which can simplify how a compound is characterised. A co-formulation lets researchers work with two well-studied components whose individual pharmacology is already documented, but the combination introduces its own formulation and ratio considerations. Neither approach is inherently superior, and this guide does not declare a winner.

The question is not which is better, but how a single engineered molecule and a two-molecule combination differ in structure while addressing the same receptor pair.

The shared GLP-1 and amylin pathways

Both candidates are discussed in the context of the GLP-1 receptor and the amylin receptor. GLP-1, or glucagon-like peptide-1, is an incretin pathway widely studied in metabolic research. Amylin is a separate peptide pathway that has become a prominent target in the current research landscape.

What makes amycretin and CagriSema comparable is that they both engage this GLP-1 plus amylin combination, just by different structural routes. This shared target pair is why the two are frequently grouped together in pipeline discussions, even though their make-up is distinct. Describing these pathways is mechanistic background only and is not a claim about any effect in people.

Development stage and trial design

Both candidates have been reported as progressing through Novo Nordisk's clinical pipeline. Amycretin has been slated to advance into later-stage development across its subcutaneous and oral formats for weight management. CagriSema has been evaluated through the multi-trial REDEFINE program, which spans different study populations and comparators.

Development stage is not fixed. Timelines shift, trials report at different times, and some studies meet their endpoints while others do not. For that reason, anyone tracking these candidates should treat stage information as a snapshot and confirm current status against primary sources such as regulator filings and the developer's own announcements.

Australian regulatory status

In Australia, both amycretin and CagriSema are investigational. Neither is approved for therapeutic use, and neither appears on the Australian Register of Therapeutic Goods (ARTG). They are supplied to researchers on a research-use-only basis for laboratory and non-human study.

A point of nuance: semaglutide, one of the two molecules inside CagriSema, is separately registered on the ARTG as a Schedule 4 prescription medicine under its own brand names. That separate registration does not extend to the CagriSema co-formulation, which remains unapproved as a combination product. Amycretin, as a distinct single molecule, is likewise not approved. Nothing in this status overview should be read as medical or legal advice.

How this fits a research setting

For laboratories, the amycretin versus CagriSema comparison is primarily a study in design philosophy: one engineered molecule acting at two receptors, versus two molecules combined to reach the same receptor pair. Documenting the differences in structure, components and development route is the kind of neutral comparison researchers use when mapping the GLP-1 and amylin landscape.

Because both are unapproved investigational agents, any handling in Australia should follow research-use-only conventions, with appropriate record-keeping and no human application. If you need regulatory or clinical guidance, consult the relevant authority or a qualified professional rather than relying on a general explainer.

Frequently asked questions